Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease
David D. Waters(San Francisco General Hospital), Jacques Lespérance(Montreal Heart Institute), Michel Lemay, Peter Gladstone(Hartford Hospital), Brian P. Kimball, Lyall Higginson(University of Ottawa)
Cited by 17
Related Papers
Effects of Hormone Replacement Therapy and Antioxidant Vitamin Supplements on Coronary Atherosclerosis in Postmenopausal Women
|JAMA|2002|576
Effect of ACAT Inhibition on the Progression of Coronary Atherosclerosis
|New England Journal of Medicine|2006|397
High-Dose Epinephrine in Adult Cardiac Arrest
|New England Journal of Medicine|1992|377